# A Roadmap for the Application of Convalescent Plasma and Hyperimmune Globulins in Emerging Viral Outbreaks

## TL;DR

This paper outlines a plan for using convalescent plasma and hyperimmune globulins during new viral outbreaks, based on lessons from past experiences like the COVID-19 pandemic.

## Contribution

The paper provides a systematic roadmap for the use of convalescent plasma and hyperimmune globulins in future viral outbreaks.

## Key findings

- Convalescent plasma and hyperimmune globulins can be rapidly prepared for use during emerging viral outbreaks.
- These therapies have been historically used in viral outbreaks and remain a viable treatment option.
- A systematic approach is needed to guide plasma transfusion and hyperimmune globulin preparation in future outbreaks.

## Abstract

The outbreak of COVID-19 took the world by surprise and dealt a serious blow to the global economy. Even today, few drugs against SARS-CoV-2 infection have been proven useful, and repurposing existing antiviral therapies remains a major research area in the treatment of the disease. During previous viral outbreaks, therapies using convalescent plasma and related products have repeatedly been used as empirical approaches. Rapid preparation of convalescent plasma and hyperimmune globulins (hIVIGs) makes these two treatment options useful in dealing with outbreaks of emerging diseases. The current study presents a systematic roadmap concerning the guidelines, criteria, and regulations involved in plasma transfusion and the preparation of hIVIGs applicable to possible future viral outbreaks.